We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Dr Reddy's Laboratories (RDY) ADR Each Representing 1/2 INR5

Sell:$13.96 Buy:$13.98 Change: $0.34 (2.38%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$13.96
Buy:$13.98
Change: $0.34 (2.38%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$13.96
Buy:$13.98
Change: $0.34 (2.38%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Contact details

Address:
8-2-337, Road No.3 Banjara Hills
HYDERABAD
500034
India
Telephone:
+91 (40) 49002900
Website:
https://www.drreddys.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RDY
ISIN:
US2561352038
Market cap:
$11.98 billion
Shares in issue:
4.17 billion
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Kallam Reddy
    Chairman of the Board
  • Gunupati Prasad
    Co-Chairman of the Board, Managing Director
  • Erez Israeli
    Chief Executive Officer
  • M. V. Narasimham
    Chief Financial Officer
  • Patrick Aghanian
    Chief Executive Officer, European Generics
  • Milan Kalawadia
    Chief Executive Officer, North America
  • M. Ramana
    Chief Executive Officer, Branded Markets (India and Emerging Countries)
  • Archana Bhaskar
    Chief Human Resource Officer
  • Phani Mitra B.
    Chief Information Officer
  • Sushrut Kulkarni
    Global Head of Integrated Product Development Organisation

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.